Update on the use of etanercept across a spectrum of rheumatoid disorders

References

• AsklingJForedCMBrandtL2007Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnn Rheum Dis6613394417261532
   PubMed Web of Science ®Google Scholar
• BaraliakosXBrandtJListingJ2005bOutcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging dataArthritis Rheum538566316342093
   PubMed Web of Science ®Google Scholar
• BaraliakosXDavisJTsujiW2005aMagnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanerceptArthritis Rheum5212162315818694
   PubMed Web of Science ®Google Scholar
• BathonJMMartinRWFleischmannRM2000A comparison of etanercept and methotrexate in patients with early rheumatoid arthritisN Engl J Med34315869311096165
   PubMed Web of Science ®Google Scholar
• BrandtJKhariouzovAListingJ2004Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanerceptJ Rheumatol31531814994401
   PubMed Web of Science ®Google Scholar
• BrandtJListingJHaibelH2005Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitisRheumatology (Oxford)44342815561737
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXListingJ2005Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanerceptArthritis Rheum5224475116052578
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXListingJ2007Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agentsArthritis Rheum576394717471540
   PubMed Web of Science ®Google Scholar
• CalinADijkmansBEmeryP2004Outcomes of a multicentre randomised trial of etanercept to treat ankylosing spondylitisAnn Rheum Dis63159460015345498
   PubMed Web of Science ®Google Scholar
• CarmonaLDescalzoMAPerez-PampinE2007All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonistsAnn Rheum Dis66880517324968
   PubMed Web of Science ®Google Scholar
• CarmonaLGómez-ReinoJJRodríguez-ValverdeV2005Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis Rheum5217667215934089
   PubMed Web of Science ®Google Scholar
• ChoyENPanayiGS2001Cytokine pathways and joint inflammation in rheumatoid arthritisN Engl J Med3449071611259725
   PubMed Web of Science ®Google Scholar
• CombeBCodreanuCFioccoU2006Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonAnn Rheum Dis6513576216606651
   PubMed Web of Science ®Google Scholar
• CombeBLandeweRLukasC2007EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis66344516396980
   PubMed Web of Science ®Google Scholar
• CombeB2007Early rheumatoid arthritis: strategies for prevention and managementBest Pract Res Clin Rheumatol21274217350542
   PubMed Web of Science ®Google Scholar
• CulyCRKeatingGM2002Etanercept. An updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritisDrugs622493253712421111
   PubMed Web of Science ®Google Scholar
• DavisJCJrvan der HeijdeDMBraunJ1995Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliaque joint biopsy specimens from patients with ankylosing spondylitisArthritis Rheum384995057718003
   PubMed Web of Science ®Google Scholar
• DavisTFriendDSmithCA2002Comparative TNF binding characteristics of etanercept (Enbrel) and infliximab (Remicade)Ann Rheum Dis61Suppl 1184
   Google Scholar
• DhillonSLyseng-WilliamsonKAScottLJ2007Etanercept: A review of its use in the management of rheumatoid arthritisDrugs6712114117521223
   PubMed Web of Science ®Google Scholar
• DixonWGSymmonsDPLuntM2007aSerious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studiesArthritis Rheum56289690417763441
   PubMed Web of Science ®Google Scholar
• DixonWGWatsonKDLuntM2007bReduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum5629051217763428
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFHallSRemission rates in subjects with active early rheumatoid arthritis1 year results of the COMET trial: combination of methotrexate and etanercept in active early rheumatoid arthritis. ACR Scientific MeetingBostonNovember 6–11, 2007Late-Breaking Abstracts, L17.
   Google Scholar
• [EMEA] European Medicines AgencyEnbrel 25 and 50 mg solution for injection: summary of product characteristics [online]URL: http://www.emea.europa.eu
   Google Scholar
• FautrelBPhamTMouterdeG2007Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritisJoint Bone Spine746273718037319
   PubMed Web of Science ®Google Scholar
• FurstDEBreedveldFCKaldenJR2007Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Ann Rheum Dis66Suppl 3iii22217934088
   PubMed Web of Science ®Google Scholar
• FurstDEWallisRBroderM2006Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionSemin Arthritis Rheum361596716884970
   PubMed Web of Science ®Google Scholar
• GenoveseMCBathonJMFleischmannRM2005Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritisJ Rheumatol3212324215996057
   PubMed Web of Science ®Google Scholar
• GenoveseMCBathonJMMartinRW2002Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesArthritis Rheum4614435012115173
   PubMed Web of Science ®Google Scholar
• GenoveseMCCohenSMorelandL2004Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis Rheum501412915146410
   PubMed Web of Science ®Google Scholar
• GormanJDSackKEDavisJCJr2002Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alphaN Engl J Med34613495611986408
   PubMed Web of Science ®Google Scholar
• HoySMScottLJ2007Etanercept, a review of its use in the management of ankylosing spondylitis and psoriatic arthritisDrugs6726093318034593
   PubMed Web of Science ®Google Scholar
• JacobssonLTTuressonCNilssonJA2007Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritisAnn Rheum Dis66670517158824
   PubMed Web of Science ®Google Scholar
• KapetanovicMCSaxneTNilssonJA2007Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patientsRheumatology (Oxford)466081117114801
   PubMed Web of Science ®Google Scholar
• KhannaDMcMahonMFurstDE2004Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?Arthritis Rheum5010405015077286
   PubMed Web of Science ®Google Scholar
• KhannaMShirodkarMAGottliebAB2003Etanercept therapy in patients with autoimmunity and hepatitis CJ Dermatolog Treat142293214660270
   PubMedGoogle Scholar
• KlareskogLvan der HeijdeDde JagerJP2004Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet3636758115001324
   PubMed Web of Science ®Google Scholar
• KremerJMWeinblattMEBankhurstAD2003Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observationsArthritis Rheum481493912794815
   PubMed Web of Science ®Google Scholar
• LovellDJGianniniEHReiffA2000Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study GroupN Engl J Med342763910717011
   PubMed Web of Science ®Google Scholar
• LovellDJGianniniEHReiffA2003Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trialArthritis Rheum482182612528122
   PubMed Web of Science ®Google Scholar
• LovellDJReiffAJonesOY2006Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisArthritis Rheum5419879416732547
   PubMed Web of Science ®Google Scholar
• MathiasSDColwellHHMillerDP2000Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placeboClin Ther221283910688396
   PubMed Web of Science ®Google Scholar
• MeasePJGoffeBSMetzJ2000Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet3563859010972371
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFX2004Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionArthritis Rheum5022647215248226
   PubMed Web of Science ®Google Scholar
• MichaudKWolfeF2007The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observationArthritis Rheum561433917469100
   PubMed Web of Science ®Google Scholar
• MohlerKMTorranceDSSmithCA1993Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonistsJ Immunol1511548618393046
   PubMed Web of Science ®Google Scholar
• MorelandLWBaumgartnerSWSchiffMH1997Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinN Engl J Med33714179219699
   PubMed Web of Science ®Google Scholar
• MorelandLWSchiffMHBaumgartnerSW1999Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med1304788610075615
   PubMed Web of Science ®Google Scholar
• MorelandLWWeinblattMEKeystoneEC2006Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experienceJ Rheumatol338546116541481
   PubMed Web of Science ®Google Scholar
• Nestorovde VriesZitnikR2004Comparative pharmacokinetics of etanercept in patients with psoriasis or rheumatoid arthritis [abstract]J Am Acad Dermatol50P147Abstract P572
   Web of Science ®Google Scholar
• OkadaSKSiegelJN2006Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritisJAMA2962201217090760
   PubMed Web of Science ®Google Scholar
• RudwaleitMListingJBrandtJ2004Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitisAnn Rheum Dis636657015037444
   PubMed Web of Science ®Google Scholar
• SchneeweissSSetoguchiSWeinblattME2007Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis Rheum5617546417530704
   PubMed Web of Science ®Google Scholar
• SetoguchiSSolomonDHWeinblattME2006Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritisArthritis Rheum5427576416947774
   PubMed Web of Science ®Google Scholar
• SorioloBPaolinoSSulliA2006Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritisAnn NY Acad Sci1069420716855169
   PubMed Web of Science ®Google Scholar
• StrangfeldAListingJ2006Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapyBest Pract Res Clin Rheumatol2011819517127203
   PubMed Web of Science ®Google Scholar
• StrangfeldAListingJRauR2007Reactivation of herpesviruses (hhv-1 and hhv-3) infections is increased in RA patients treated with adalimumab or infliximabAnn Rheum Dis66Suppl IIOP0214
   Google Scholar
• TubachFSalmonDRavaudP2007Definitive results of the National French prospective RATIO 3-year observatory on tuberculosis inpatients treated with TNF blockers: the risk persists but depends on the drugArthritis Rheum56S426
   Google Scholar
• van der HeijdeDKlareskogLLandewéR2007Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritisArthritis Rheum5639283918050208
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKlareskogLSinghA2006bPatient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trialAnn Rheum Dis653283416079172
   PubMed Web of Science ®Google Scholar
• van der HeijdeKlareskogLRodriguez-ValverdeV2006aComparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trialArthritis Rheum5410637416572441
   PubMed Web of Science ®Google Scholar
• van RielPLTaggartAJSanyJ2006Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE studyAnn Rheum Dis6514788316464988
   PubMed Web of Science ®Google Scholar
• WeinblattMCombeBCovucciA2006Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled studyArthritis Rheum5428071616947384
   PubMed Web of Science ®Google Scholar
• WeinblattMEKremerJMBankhurstAD1999A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med34025399920948
   PubMed Web of Science ®Google Scholar
• WolfeFMichaudK2007Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analysis from a large US observational studyArthritis Rheum5628869517729297
   PubMed Web of Science ®Google Scholar
• WoolacottNFKhadjesariZCBruceIN2006Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic reviewClin Exp Rheumatol245879317181932
   PubMed Web of Science ®Google Scholar
• ZhouH2005Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion proteinJ Clin Pharmacol45490715831771
   PubMed Web of Science ®Google Scholar